small molecule

ODOMZO

SONIDEGIB PHOSPHATE

Loss of exclusivityMarch 2036latest FDA-listed patent expiry
CompanySUN PHARMACEUTICAL INDUSTRIES LTD

Drug detail

Brand nameODOMZO
Active ingredientSONIDEGIB PHOSPHATE
StrengthEQ 200MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2015
Marketing statusRX

Listed patents

PatentExpiresType
10266523March 2036substance, product
8063043September 2029substance, product
8178563July 2029substance

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ODOMZO patent cliff — loss of exclusivity March 2036 | CliffBio